Osamura R Y, Watanabe K
Acta Pathol Jpn. 1986 Aug;36(8):1131-7. doi: 10.1111/j.1440-1827.1986.tb02834.x.
In order to establish the experimental model for human prolactinomas and its bromocriptine treatment, estrogen-induced prolactinoma was produced in the female Wistar rats, in which daily bromocriptine treatment was given for a week, 3 days or 1 day (24 hours). The prolactinoma was produced by giving 5 mg estrogen depot every four weeks. The rats were killed at 4, 12, 20, and 24 weeks after the initial injection of the estrogen. By immunoelectron microscopy, in the estrogen induced prolactinoma, PRL was localized in well developed lamellar or whorling rough endoplasmic reticulum (RER) and Golgi saccules. In the rats treated with bromocriptine for a week, the serum PRL levels were lowered and the atrophied cytoplasm was filled with secretory granules containing PRL. These data were comparable to those of the human prolactinomas and the present experiment will serve as an animal model for studying the morphofunctional changes of human prolactinomas induced by bromocriptine treatment. The experiment with bromocriptine treatment for 24 hours supported the proposed mechanism that bromocriptine evokes inhibition of exocytosis followed by continuous granule formation in Golgi complexes and subsequently lowers synthesis of PRL.
为建立人催乳素瘤及其溴隐亭治疗的实验模型，在雌性Wistar大鼠中制备雌激素诱导的催乳素瘤，对其分别给予溴隐亭每日治疗一周、三天或一天（24小时）。每四周给予5mg长效雌激素以制备催乳素瘤。在首次注射雌激素后的4周、12周、20周和24周处死大鼠。通过免疫电子显微镜观察，在雌激素诱导的催乳素瘤中，催乳素定位于发育良好的板层状或涡旋状粗面内质网（RER）和高尔基体囊泡中。在接受溴隐亭治疗一周的大鼠中，血清催乳素水平降低，萎缩的细胞质充满了含有催乳素的分泌颗粒。这些数据与人类催乳素瘤的数据相当，本实验将作为研究溴隐亭治疗诱导的人催乳素瘤形态功能变化的动物模型。溴隐亭治疗24小时的实验支持了以下提出的机制：溴隐亭引起胞吐作用的抑制，随后在高尔基体复合物中持续形成颗粒，进而降低催乳素的合成。
